Evaluate the Effect of ReSpace™ Hydrogel on Reducing Rectal Radiation Dose in Radiotherapy for Cervical Cancer

Inclusion Criteria:

* • Patients with pathologically confirmed cervical cancer who must be scheduled to undergo radical radiotherapy by means of intensity-modulated radiotherapy combined with 3D brachytherapy.

  * Karnofsky score ≥ 70.
  * Subjects aged ≥ 18 years and ≤ 75 years.
  * Subjects must be able to cooperate in completing the entire study.
  * The subjects' pelvic and abdominal cavity and joints are free of metal implants and can tolerate MRI.
  * No contraindications to CT scanning.
  * Subjects must be able to understand the purpose of the trial, voluntarily participate and sign an informed consent form

Exclusion Criteria:

* •Subjects who have received prior pelvic radiotherapy.

  * Subjects whose target tumors have been previously treated (chemotherapy, immunotherapy, surgical treatment, etc.)
  * Subjects with other primary malignancies
  * Subjects with contraindications to radiotherapy, as determined by the investigators
  * Subjects with injection site infections.
  * Subjects who are allergic to the ingredients of the device.
  * Subjects whose tumors invade the injection site and affect the injection process and injection safety, as determined by the investigators
  * Persons with severe mental illness, cognitive impairment and thinking disorders.
  * Participants in other drug clinical trials or medical device clinical trials 1 month prior to screening
  * Pregnant or lactating women or those who plan to get pregnant within the last six months
  * Subjects who cannot be followed up as prescribed by the doctor
  * Other conditions that, in the judgment of the investigator, make the subject unsuitable for enrollmen